Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Re: Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match

    Dear Editor,

    I noticed in Figure 2 of the article, “Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match”, that Taiwan was shown among “countries with no response or no access to their guidelines”. As the main coordinator of Taiwan’s COVID-19 Therapeutic Guideline Expert Committee, I am eager to share with your readers how we developed and revised our national guideline (NG) during January 2020 to December 2023, with the latest version being version 25 (1). Our committee was composed of experts from different fields, including clinicians (infection specialists, pulmonologists, intensivists), infection control specialists, laboratory experts, etc. We diligently reviewed the latest evidence on COVID-19 therapeutics, and revised the guideline timely.

    For example, in version 2 of our NG, published on 2 February 2020, we recommended that lopinavir/ritonavir may be considered for patients with severe pneumonia or acute respiratory distress syndrome based on in vitro study results of other coronaviruses, which was the best evidence available at the beginning of the COVID-19 pandemic. The recommendation was retracted in version 5, released on 26 March 2020, soon after results of a clinical trial published on 18 March 2020 showing this was ineffective. Hydroxychloroquine was also once recommended by our NG and later removed after solid evidence against using this drug for COVID-19 treatment became available (...

    Show More
    Conflict of Interest:
    None declared.